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Editor’s key points
† The signs of local
anaesthetic (LA) toxicity
may be masked by
general anaesthesia, and
specific monitoring is
recommended.
† This study in children
found that a test dose of
LA must contain
epinephrine for
intravascular injection to
be detected.
† The effect depended on
patient age.
† Monitoring of heart rate,
arterial pressure, and ECG
for T-wave changes
should be mandatory
during test dose injection.
Background. The aim of this study was to investigate ECG and haemodynamic alterations
provoked by a test dose of bupivacaine, epinephrine, and their combination.
Methods. Paediatric patients undergoing general anaesthesia were randomized into three
groups. After anaesthesia induction and tracheal intubation, 0.2 ml kg21 (max. 3 ml) of
the corresponding test solution was i.v. injected: bupivacaine 0.125% (Group B),
bupivacaine 0.125% plus epinephrine 1:200 000 (Group BE), or epinephrine 1:200 000
(Group E). ECG was printed and analysed post hoc. Non-invasive arterial pressure (AP)
was measured at 1 and 2 min after test dose injection. Increases in T-wave of ≥25%, in
heart rate (HR) of ≥10 beats min21, and in systolic AP of ≥15 mm Hg above baseline
value were considered a positive result.
Results. A total of 105 children aged 0.2–16 (median 6.8) yr were enrolled. Test dose
injection provoked T-wave elevation in 0%, 85%, and 89% of patients in Groups B, BE,
and E, respectively. A positive increase in HR was found in 0%, 68%, and 76%. A positive
increase in AP at 1 min was found in 0%, 88%, and 94% and at 2 min in 0%, 42%, and
59%. A decrease in HR of ≥10 beats min21 was observed in 6%, 76%, and 69%.
Alterations in T-wave and HR were significantly influenced by age.
Conclusions. ECG and haemodynamic alterations after i.v. injection of a local anaesthetic
test dose were significantly influenced by epinephrine. T-wave elevation, increase in AP,
and changes in HR are highly reliable variables, particularly when age is taken into account.
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When combined general and regional anaesthesia is used for
intra- and postoperative pain relief in children, neurological
signs of local anaesthetic (LA) toxicity in the case of inadvertent
intravascular administration of LA are blunted by general an-
aesthesia, muscle paralysis, or both.1 Therefore, to timely
detect an inadvertent intravascular administration of LA,
other than neurological signs are needed to avoid sudden
haemodynamic collapse by LA intoxication.2 3 Animal
research in small pigs has shown that the systemic application
of a standardized small test dose of bupivacaine with epineph-
rine or epinephrine alone but not bupivacaine alone results in an
increase in T-wave amplitude in the ECG and in heart rate (HR)
increase.4 The aim of this study is to elucidate whether these
ECG findings and haemodynamic effects found in small pigs
provoked by a test dose of epinephrine, bupivacaine, and their
combination are reproducible from infancy to adolescence.
Methods
The study was approved by the local ethics committee
(KEK-ZH-No. 2009-0025) and registered on ClinicalTrials.gov
(NCT 01091766). Paediatric patients aged from 1 month to
16 yr, ASA classification I, undergoing an elective invasive
procedure requiring general anaesthesia and tracheal intub-
ation were recruited for this prospective randomized clinical
trial. The patients were grouped according to age: infants
(Group 1, n¼15), 1–6 yr (Group 2, n¼30), 6–12 yr (Group 3,
n¼30), and 12–16 yr (Group 4, n¼30). Less infants were
included in Group 1 compared with other groups in order to
guarantee a continuous distribution of age. Written parental
and patient (Group 4) consent was obtained.
Premedication and route of induction (i.v. or inhalation)
of general anaesthesia depended on the age and preference
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of the patient. Tracheal intubation was performed in
all patients after neuromuscular block using atracurium
(Tracrium; GlaxoSmithKline, Mu¨nchenbuchsee, Switzerland).
Anaesthesia was maintained by sevoflurane (Sevorane;
Abbott AG, Baar, Switzerland) 2.5 vol% in oxygen/nitrous
oxide (ratio 1:2). No atropine was given to any patient
before test dose injection.
Monitoring consisted of pulse oximetry, ECG, non-invasive
arterial pressure (AP) measurement, and end-tidal gas ana-
lysis (sevoflurane, O2, N2O, and CO2). For application of the
three different test solutions, the four age-dependent
groups were each randomized into three groups. Group B
received plain bupivacaine 0.125% (Bupivacaine 0.125%; Sin-
tetica S.A., Mendrisio, Switzerland), Group BE received bupiva-
caine 0.125%+epinephrine 1:200 000, and Group E received
only epinephrine 1:200 000 (Adrenalin; Sintetica S.A.).
Under stable cardiopulmonary and anaesthesia conditions,
0.2 ml kg21 (max. 3 ml) of the corresponding test solution
was i.v. administered followed by an injection of 10 ml
normal saline. The amount of 0.2 ml kg21 (max. 3 ml) test
solution corresponded to the routinely used test dose of
bupivacaine 0.125%+epinephrine 1:200 000 in the author’s
anaesthesia department before injection of the total
amount of LA for regional anaesthesia blocks. The two
anaesthetists injecting the study medication were not
blinded to the study drug for safety reasons in the case of
an adverse event and were not involved in anaesthetic care
of the study patient. ECG traces I and II were monitored
and continuously printed for post hoc analysis by a single,
blinded anaesthetist. Initial, maximal, and minimal HR and
non-invasively measured AP were noted before and at 1
and 2 min after test dose injection.
The primary outcome was T-wave alterations. The second-
ary outcomes were changes in HR and AP. According to
current literature,2 5 6 increases of ≥25% in T-wave ampli-
tude, ≥10 beats min21 in HR, and ≥15 mm Hg in systolic
AP above baseline were considered each a positive response.
In addition, a decrease in HR of ≥10 beats min21 was taken
as a positive finding.
The computer package NCSS 2007 (Version 07.1.20, Kays-
ville, UT, USA) was used for statistical analysis. A P-value of
≤0.05 was considered significant. Linear and generalized
linear models were performed with the software R (Version
2.11.1) using the packages lmtest7 and nlme.8 Model selec-
tion was based on Akaike’s information criterion and visual
checking of the residuals. The results of the models are
given in estimated mean effects and standard errors (SEs).
P-values were derived from likelihood ratio tests.
Results
Overall 105 children were included in the study (Table 1). All
patients aged.6 months received premedication with midazo-
lam (0.5 mg kg21, max 15 mg, reduced dose in agreement with
the anaesthetist in charge of the patient; applied orally or
rectally as decided by the child/parents) except one 8-yr-old
boy in Group BE. Inhalation induction of anaesthesia with
sevoflurane was chosen in all except 17 patients (13 of them
aged 12–16 yr), who had an i.v. induction with propofol and
alfentanil (10 mg kg21) or fentanyl (2 mg kg21). In one boy
(aged 14), randomized into study group BE, a test dose was
not injected because of the therapy used to treat hypotension
after induction of anaesthesia and data from this patient were
excluded from further data analysis. During the study period,
no critical or adverse events were observed or had to be treated.
At baseline, using analysis of variance, no significant dif-
ferences between the three treatment groups were detected
for age (P¼0.990), systolic (P¼0.491) and diastolic (P¼0.453)
AP, and HR (P¼0.902).
The incidence of positive T-wave elevation to test dose (all
ages) was 0% in Group B, 85% in Group BE, and 89% in Group
E (Table 2) (P,0.0001, Fisher’s exact test). A positive T-
elevation to intravascular epinephrine administration (IVEA)
occurred in median 20 (range 14–34) s. The median baseline
Table 1 Patient characteristics, subdivided according to age group and study drug
Age group Study drug n Age Weight M/F
0–1 yr All 15 0.5 (0.2–1.0) 6.9 (4.1–9.5) 13/2
B 5 0.5 (0.2–0.6) 7.6 (6.0–8.7) 5/0
BE 5 0.5 (0.3–0.8) 6.9 (6.5–9.0) 4/1
E 5 0.2 (0.2–1.0) 5.1 (4.1–9.5) 4/1
1–6 yr All 30 3.6 (1.2–5.9) 16.7 (8.7–23.0) 21/9
B 10 3.6 (1.8–4.9) 17.3 (13.0–23.0) 7/3
BE 10 2.8 (1.7–5.5) 13.5 (11.2–21.0) 7/3
E 10 3.7 (1.2–5.9) 15.9 (8.7–19.9) 7/3
6–12 yr All 30 7.8 (6.0–11.8) 27.0 (18.0–56.0) 16/14
B 10 7.6 (6.1–11.1) 25.5 (18.0–52.3) 6/4
BE 10 8.5 (6.1–11.3) 28.0 (18.6–45.5) 5/5
E 10 7.2 (6.0–11.8) 26.5 (18.0–56.0) 5/5
12–16 yr All 30 14.0 (12.0–16.3) 54.5 (34.0–83.0) 14/16
B 10 14.0 (12.0–16.3) 52.0 (36.0–80.5) 4/6
BE 10 14.2 (12.1–15.5) 55.0 (35.5–78.0) 7/3
E 10 13.6 (12.4–15.9) 53.5 (34.0–83.0) 3/7
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T-wave in ECG lead I was 0.15 (range 0.02–0.45) and 0.25
(0.05–0.70) mV in ECG lead II. Relative increases in T-
amplitude in lead II were larger than in lead I (Table 3). In
Groups BE and E, age was significantly associated with the
probability of a positive T-wave elevation (P,0.0001), with
older children having a reduced probability to show a positive
T-elevation compared with the younger ones (Fig. 1). Patients
of Groups BE and E did not differ (P¼0.625). Gender was not
significant (P¼0.621). Typical ECG traces of an infant and an
adolescent are shown in Figure 2.
A positive HR increase to test dose (all ages) were 0% in
Group B, 68% in Group BE, and 76% in Group E (Table 2).
Groups BE and E had a significantly higher maximum increase
in HR during the observation period with 13.2 (SE 1.7) and 16.1
(SE 1.7) beats min21, respectively (both P,0.0001), compared
with Group B. Three highly influential data points affecting
the age effect were removed. The maximum increase in HR
was significantly influenced by age with a decrease of 0.3
(SE 0.14) beats min21 per year (P¼0.026), but not by sex
(P¼0.391) nor by i.v. induction (P¼0.114).
A positive decrease in HR (.10 beats min21) after test dose
(all ages) was found in 6% in Group B, 76% in Group BE, and
69% in Group E (Table 2). Groups BE and E had a significantly
greater decrease in HR during the observation period with
14.1 (SE 2.1) and 12 (SE 2.1) beats min21, respectively (both
P,0.0001), compared with Group B (Table 3). The maximum
decrease in HR was significantly influenced by age with a de-
crease of 0.5 (SE 0.17) beats min21 per year (P¼0.003), but not
by gender (P¼0.157) nor by i.v. induction (P¼0.137).
Intermittent loss of P-wave was observed in Groups BE
and E (Table 3). In 10 patients, loss of P-wave occurred
during HR increase at 26.5 s (range 23–30) after IVEA. In
seven patients, P-wave disappeared at 62.5 (44–85) s after
IVEA and during the decrease in HR.
A positive systolic AP increase to the test dose after 1 min
(all ages) was seen in 0% in Group B, 88% in Group BE, and
94% in Group E (Table 2). Groups BE and E had a significant
increase of 35.8 (SE 6.26) and 50.97 (SE 6.26) mm Hg in systol-
ic AP compared with Group B (both P,0.0001) after 1 min
(Table 3). The interaction between the group effect and i.v.
induction was found to be significant (P¼0.007). The effect
of the interaction was to decrease the mean difference for
a patient in Group E without i.v. induction from 50.1 to 29.4
mm Hg. Neither age (P¼0.303) nor gender (P¼0.115) was
significantly associated with the difference in systolic AP
after 1 min. After 2 min, the increases in Groups BE and E
were less prominent with significant increases of 19.03
(SE 2.03) and 18.51 (SE 2.01) mm Hg compared with Group B
(both P,0.0001). The interaction between the group effect
and i.v. induction was no longer significant (P¼0.583).
Neither age (P¼0.503) nor gender (P¼0.253) had a signifi-
cant influence.
Diastolic AP changes: after 1 min, Groups BE and E had a
significant increase in diastolic AP with 26.3 (SE 3.4) and 22.15
(SE 3.6) mm Hg compared with Group B (both P,0.0001).
Boys had a significantly lower diastolic AP with 5.1 (SE 1.8)
mm Hg less than girls (P¼0.001). The interaction between
the group effect and age was significant (P¼0.017). The
effect of the interaction was to decrease the mean difference
for a patient in Group BE by 1.1 mm Hg (P¼0.005) per year.
Without three highly influential data points, the effect of
the i.v. induction was not significant (P¼0.235). After 2
min, the increases in Groups BE and E were less prominent
with significant increases of 10.05 (SE 1.8) and 7.08 (SE 1.8)
mm Hg compared with Group B. The effect of age was
found to be significant (P,0.001) with a decrease of 0.59
(SE 0.15) mm Hg per year. Neither gender (P¼0.149) nor i.v.
induction (P¼0.272) was found to have a significant effect
on diastolic AP after 2 min.
To summarize, the inclusion of T-wave and HR allows de-
tection of an epinephrine-containing test dose with a reliabil-
ity of 100% (Table 4).
Table 2 Number (%) of positive reactions such as T-wave elevation of ≥25% in the ECG, increase or decrease in HR of ≥10 beats min21, and
increase in systolic AP of ≥15 mm Hg at 1 (AP 1) and 2 (AP 2) min after test dose injection. *Because of a technical problem, results of one patient
are missing
Study group Patients T-wave ECG I T-wave ECG II HR increase HR decrease AP 1 AP 2
B All (n¼35) 0 (0) 0 (0) 0 (0) 2 (6) 0 (0) 0 (0)
0–1 yr (n¼5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
1–6 yr (n¼10) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
6–12 yr (n¼10) 0 (0) 0 (0) 0 (0) 1 (10) 0 (0) 0 (0)
12–16 yr (n¼10) 0 (0) 0 (0) 0 (0) 1 (10) 0 (0) 0 (0)
BE All (n¼34) 25 (76) 28 (85) 23 (68) 26 (76) 30 (88) 14 (42)
0–1 yr (n¼5) 5 (100) 5 (100) 5 (100) 1 (20) 5 (100) 2 (40)
1–6 yr (n¼10) 10 (100) 10 (100) 6 (60) 8 (80) 10 (100) 4 (40)
6–12 yr (n¼10) 9* (100) 9* (100) 5 (50) 9 (90) 7 (70) 5* (55)
12–16 yr (n¼9) 1 (11) 4 (44) 7 (78) 8 (89) 8 (89) 3 (33)
E All (n¼35) 26 (74) 31 (89) 26 (76) 24 (69) 32 (94) 20 (59)
0–1 yr (n¼5) 5 (100) 5 (100) 4 (80) 0 (0) 5 (100) 3 (60)
1–6 yr (n¼10) 9 (90) 10 (100) 9 (90) 7 (70) 9 (90) 5 (50)
6–12 yr (n¼10) 9 (90) 10 (100) 5* (55) 8 (80) 9* (100) 6* (67)
12–16 yr (n¼10) 3 (30) 6 (60) 8 (80) 9 (90) 9 (90) 6 (60)
ECG alterations caused by local anaesthetic test dose BJA
285
Discussion
The main findings in this study were that after i.v. injection of
an LA test dose, ECG and haemodynamic alterations were
significantly influenced by epinephrine. I.V. injection of a
test dose of plain bupivacaine had no effect on ECG, AP, or
HR. After IVEA, manifestation of elevated T-wave and
changes in HR were age-dependent, whereas an increase
in systolic pressure was age-independent. A combination of
all three of these cardiovascular variables allowed reliable
detection of IVEA in all patients investigated.
Observation of needle and catheters for passive backflow
of blood or the active aspiration of blood from needles or
catheters in regional anaesthesia techniques have a failure
rate of 57% to detect intravascular needle/catheter position.9
Although ultrasound-guided regional anaesthesia promises
visual control of LA injection, bupivacaine-induced toxicity
has been described.3 Similarly, the use of a less toxic LA
may reduce the risk of systemic intoxication, but there are
reports of LA toxicity, despite using ropivacaine or levobupi-
vacaine.10 Thus, the ECG and haemodynamic alterations
play an important role in the early detection of inadvertent
intravascular LA administration.
Recent animal studies demonstrate that T-wave elevation
associated with LA test dose is caused by epinephrine and
Table 3 Quantitative changes in T-wave (ECG traces I and II), HR, and systolic AP at 1 and 2 min after test dose injection and number of patients
with intermittent loss of P-wave. Results are median (range)
Study
drug
Patients T-wave ECG I
(elevation
in% above
baseline)
T-wave ECG II
(elevation
in% above
baseline)
HR increase
(beats
min21 above
baseline)
HR decrease
(beats min21
below baseline)
AP 1
(changes
in mm Hg)
AP 2
(changes
in mm Hg)
Loss of
P-wave
(number of
pat.)
B All (n¼35) 0 (0%)
0–1 yr
(n¼5)
0 (0–17) 0 (0–17) 0 (0–0) 25 (26 to 24) 21 (25 to 3) 21 (25 to 1) 0 (0%)
1–6 yr
(n¼10)
0 (0–0) 0 (0–0) 0 (0–2) 24 (26 to 22) 0 (26 to 6) 0 (28 to 6) 0 (0%)
6–12 yr
(n¼10)
0 (0–0) 0 (0–0) 0 (0–5) 24 (210 to 0) 2.5 (25 to 8) 0 (28 to 7) 0 (0%)
12–16 yr
(n¼10)
0 (0–0) 0 (0–0) 0 (0–2) 25 (210 to 21) 23 (223 to 5) 21.5 (219 to 7) 0 (0%)
BE All (n¼34) 6 (18%)
0–1 yr
(n¼5)
166 (83–167) 200 (100–225) 27 (13–35) 24 (219 to 0) 29 (21–61) 14 (6–45) 1 (20%)
1–6 yr
(n¼10)
100 (25–250) 175 (67–275) 12.5 (4–26) 219.5 (245 to 25) 30.5 (20–44) 14 (7–26) 1 (10%)
6–12 yr
(n¼10)
150 (502400) 145 (25–700) 9.5 (1218) 222 (236 to 23) 26 (11–44) 15 (5–31) 2 (20%)
12–16 yr
(n¼9)
0 (0–300) 0 (0–300) 15 (5237) 217 (229 to 29) 25 (10–58) 9 (5–42) 2 (22%)
E All (n¼35) 11 (31%)
0–1 yr
(n¼5)
133 (100–366) 140 (133–200) 27 (9–44) 0 (216 to 0) 27 (25–49) 16 (12–28) 0 (0%)
1–6 yr
(n¼10)
116.5 (0–300) 200 (50–400) 19.5 (8–35) 216.5 (223 to 25) 26.5 (11–38) 15 (7–25) 2 (20%)
6–12 yr
(n¼10)
100 (0–200) 145 (29–250) 10 (0–39) 221.5 (243 to 0) 29 (18–66) 18 (8–37) 5 (50%)
12–16 yr
(n¼10)
0 (0–200) 39.5 (0–350) 15.5 (7–28) 222 (232 to 29) 34.5 (14–62) 17 (7–30) 4 (40%)
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Fig 1 Probability of occurrence of T-elevation (ECG lead II) after
i.v. injection of an epinephrine-containing test dose (BE, E)
related to patient’s age. Green dotted lines indicate 95% confi-
dence interval.
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that a test dose of plain bupivacaine did not alter the ECG.4
In contrast, T-elevations provoked by plain bupivacaine
occur after intravascular injection of a large, potentially
toxic dose.11 The current study in children confirms the
results from animal investigations.4
In the past, studies investigating the sensitivity of an LA
test dose in children have reported different and not
always convincing sensitivities of T-elevation, AP, and HR to
detect intravascular injection.2 Owing to possible fatal conse-
quences of a systemic LA intoxication, the use of an
epinephrine-containing test dose has been recommended
anyhow,2 12 13 but due to unequal results and weak evidence,
it is often not adhered to in clinical practice (several personal
communications). Confounding factors of the test dose
effects observed in previous studies might be related to the
anaesthetic agent used, the administration of atropine, pre-
medication, patent’s age and sex, the ECG lead observed, the
LA investigated, or the amount of epinephrine applied.
Therefore, the results have to be interpreted within the spe-
cific setting. Polaner and colleagues14 investigated positive
intravascular test dose criteria during propofol–remifentanil
anaesthesia and obtained quite different results compared
with the current study conducted during sevoflurane anaes-
thesia. Thus, our results are only valid under sevoflurane-
based anaesthesia.
In several investigations, the ECG lead II was the preferred
lead to assess T-wave elevations.6 15 16 There is only one
study investigating ECG lead and usefulness of the T-wave
criterion in anaesthetized children aged 6–49 months.17
The authors conclude that the ECG lead does not affect
Fig 2 ECG traces lead I and II before (left) and after (right) injection of a test dose bupivacaine+epinephrine. (A) 6-month-old boy. (B)
13.2-yr-old boy.
Table 4 Number (%) of positive reactions upon test dose injection if multiple variables were combined. *In one patient, max. HR and AP at 1 min
(AP 1) failed to be recorded
Study drug Patients T-wave or
HR increase
T-wave or HR increase
or HR decrease
T-wave or
AP 1
HR increase or
AP 1
HR increase or HR
decrease or AP 1
B All (n¼35) 0 (0) 2 (6) 0 (0) 0 (0) 2 (6)
0–1 yr (n¼5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
1–6 yr (n¼10) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
6–12 yr (n¼10) 0 (0) 1 (10) 0 (0) 0 (0) 1 (10)
12–16 yr (n¼10) 0 (0) 1 (10) 0 (0) 0 (0) 1 (10)
BE All (n¼34) 33 (97) 34 (100) 33 (97) 31 (91) 33 (97)
0–1 yr (n¼5) 5 (100) 5 (100) 5 (100) 5 (100) 5 (100)
1–6 yr (n¼10) 10 (100) 10 (100) 10 (100) 10 (100) 10 (100)
6–12 yr (n¼10) 10 (100) 10 (100) 10 (100) 8 (80) 9 (90)
12–16 yr (n¼9) 8 (89) 9 (100) 8 (89) 8 (89) 9 (100)
E All (n¼35) 35 (100) 35 (100) 35 (100) 33 (97) 35 (100)
0–1 yr (n¼5) 5 (100) 5 (100) 5 (100) 5 (100) 5 (100)
1–6 yr (n¼10) 10 (100) 10 (100) 10 (100) 10 (100) 10 (100)
6–12 yr (n¼10) 10 (100) 10 (100) 10 (100) 9* (100) 10 (100)
12–16 yr (n¼10) 10 (100) 10 (100) 10 (100) 9 (90) 10 (100)
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recognition of T-elevation. In the current study, we found a
slight superiority of lead II over lead I in adolescents but
not in younger children. Tanaka and Nishikawa6 found a sig-
nificant negative correlation between the patient’s age and
increase in T-wave. In the current study, the appearance of
a positive T-elevation was age-dependent too with a high
reliability up to about 12 yr of age. In adults, a decrease of
≥25% of T-wave amplitude is the typical reaction upon injec-
tion of an epinephrine-containing test dose.18 According
to the literature,6 15 maximal change in T-wave amplitude
occurred within 1 min of test dose administration. As
reported, T-elevation most often was the first sign, followed
by HR increase and later on by changes in AP.2 Current
results are comparable with other reports,9 which found a
transient increase in T-wave of 33–250% (mean 157%)
lasting over 15–30 s.
False-negative results for HR increase to detect intravas-
cular injection of an epinephrine-containing test dose were
reported to be 29% of children during halothane anaesthe-
sia.19 Other authors using sevoflurane for general anaesthe-
sia found a sensitivity of 71%16 and 100%,6 respectively. The
current investigations showed a remarkable age-dependency
of HR upon test dose injection. As observed in the current
study, secondary HR decrease and loss of P-wave are
reported in the literature.12
Reported mean maximal increases in systolic AP of 225
and 36 mm Hg17 are consistent with our results 1 min after
test dose injection. The values obtained after 2 min were
remarkably lower, most likely due to the short half-life of
epinephrine. Therefore, it is important to perform AP meas-
urement at 1 min intervals during injection of test dose
and remaining LA volume.
Most studies investigating the effects of an i.v.
injected epinephrine-containing test dose in children use
epinephrine in a dose of 0.5 mg kg21.5 6 14 16 17 19 Recom-
mendations for clinical use2 are based on these observa-
tions. In daily practice, remarkably higher test doses were
applied.9 20 As proposed by Gerheuser and Roth,12 in the
author’s institution, a test dose of 0.2 ml kg21 LA with epi-
nephrine 5 mg ml21 has been used routinely for many
years, providing excellent safety with no systemic LA intoxi-
cation and no adverse events observed upon test dose
injection.
The clinical implications of this study are that LA test dose
must contain epinephrine to detect intravascular injection by
ECG and by changes in HR and AP. ECG monitoring is manda-
tory and lead II might be preferable to lead I. Not solely an
increase in HR but also a decrease can be associated by intra-
vascular test dose injection and has to be taken as a positive
result. Most of the test dose effects are age-dependent in dif-
ferent extents. Therefore to achieve best safety profile, mul-
tiple variables have to be observed.
In conclusion, this study demonstrates that ECG and
haemodynamic alterations are significantly influenced
by epinephrine-containing test doses. Since effects on
T-elevation, HR, and BP are age-dependent, all three para-
meters should be assessed to detect intravascular injection
of an epinephrine-containing test dose with a reliability of
100%.
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